Bleeding rates, healthcare utilization, and costs among patients with hemophilia a without inhibitors treated with concomitant octocog alfa or extended half-life factor VIII while on emicizumab prophylaxis

Key Points

• The research aims to compare the costs and healthcare utilization between different factor VIII treatments for hemophilia A patients without inhibitors on emicizumab prophylaxis.
• Comparison of bleeding rates and healthcare costs among patients using octocog alfa and extended half-life factor VIII.
• Focus on pharmacy costs associated with different treatments.
• Octocog alfa showed significantly lower pharmacy costs than extended half-life factor VIII.
• Concomitant factor VIII choice did not substantially influence bleeding rates or healthcare resource utilization.